In pancreatic cancer, down-regulation of METTL16 leads to decreased m6A modification of cyclin-dependent kinase inhibitor 1A (CDKN1A, also known as p21) mRNA, which in turn reduces the expression of the p21 protein. The gene discussed is CDKN1A; the disease is familial pancreatic carcinoma.